Stockreport

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF Long-term evaluable patients demonstrate ongoing complete response of 7 and 15 months after receiving a total of eight doses four cycles of CD19 CAR-NK plus rituximab, [Read more]